Search Results for: 127

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results

November 13, 2023 08:00 ET – VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma remains on track to complete enrollment in the first half of 2024; multiple patients have received second doses of VCN-01, which continues to be well tolerated with a safety profile consistent with […]

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results Read More »

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del tercer trimestre de 2023

November 13, 2023 08:00 ET – VIRAGE, el ensayo clínico de fase 2b de VCN-01 en combinación con quimioterapia para el adenocarcinoma ductal de páncreas metastásico, sigue el curso previsto para completar la inscripción en el primer semestre de 2024; muchos pacientes han recibido la segunda dosis de VCN-01, que sigue siendo bien tolerado y mantiene

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del tercer trimestre de 2023 Read More »

Our Science

The Theriva™ Difference Theriva is developing highly differentiated oncolytic adenoviruses that are designed to overcome the challenges of accessibility, availability, and administration and can potentially enable multiple dosing to improve efficacy. The unique therapeutic properties of Theriva’s oncolytic viruses represent a new class of cancer treatments that are designed to selectively destroy tumor cells and

Our Science Read More »

FAQs

What is Theriva™ Biologics stock symbol? Our stock is traded on the NYSE American under the symbol TOVX. Can I buy stock directly from Theriva Biologics? No, you will need to contact a licensed stock broker or use an online trading account. Where is Theriva Biologics located? 9605 Medical Center Dr.Suite 270Rockville, MD 20850 When

FAQs Read More »

Synthetic Biologics to Report 2021 First Quarter Operational Highlights and Financial Results on May 5, 2021

— Conference Call Scheduled for Wednesday, May 5, 2021 at 4:30 p.m. ET — ROCKVILLE, Md., April 28, 2021 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the Company

Synthetic Biologics to Report 2021 First Quarter Operational Highlights and Financial Results on May 5, 2021 Read More »

Synthetic Biologics to Report 2019 Third Quarter Operational Highlights and Financial Results on November 4, 2019

— Conference Call Scheduled for Monday, November 4, 2019 at 4:30 p.m. ET — ROCKVILLE, Md., Oct. 28, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the Company intends

Synthetic Biologics to Report 2019 Third Quarter Operational Highlights and Financial Results on November 4, 2019 Read More »

Synthetic Biologics Reports Second Quarter 2019 Operational Highlights and Financial Results

— Announced Clinical Trial Agreement with Washington University School of Medicine to Conduct a Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients — — Conference Call Today, August 8, 2019, at 4:30 p.m. (ET) — ROCKVILLE, Md., Aug. 8, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company

Synthetic Biologics Reports Second Quarter 2019 Operational Highlights and Financial Results Read More »

Synthetic Biologics to Report 2019 Second Quarter Operational Highlights and Financial Results on August 8, 2019

— Conference Call Scheduled for Thursday, August 8, 2019 at 4:30 p.m. ET — ROCKVILLE, Md., Aug. 1, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its operational highlights

Synthetic Biologics to Report 2019 Second Quarter Operational Highlights and Financial Results on August 8, 2019 Read More »

Synthetic Biologics Announces Allowance of Key U.S. Patent Covering SYN-010 Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)

— Allowance of Patent Provides Exclusive Method of Use Protection Until at Least 2034 — ROCKVILLE, Md., June 27, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the U.S. Patent and Trademark Office

Synthetic Biologics Announces Allowance of Key U.S. Patent Covering SYN-010 Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) Read More »

Synthetic Biologics Reports 2015 Year End Operational Highlights and Financial Results

— Reported Positive Topline Data from Phase 2 Clinical Trials of SYN-010 for Irritable Bowel Syndrome with Constipation and SYN-004 for Prevention of C. difficile Infection and Antibiotic-Associated Diarrhea — — Expect to Initiate Phase 3 Clinical Trials in 2016 — — Conference Call Today, March 10, 2016, at 4:30 p.m. (EST) — ROCKVILLE, Md.,

Synthetic Biologics Reports 2015 Year End Operational Highlights and Financial Results Read More »